Please assess the completion status of the following clinical trial:

Trial Title: Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically documented squamous cell carcinoma involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx~* Newly diagnosed, locally advanced stage head and neck cancer (unresectable/unresected disease); American Joint Committee on Cancer \[AJCC\] Stage III, IVA or IVB amenable to radiotherapy with concurrent chemotherapy as the definitive treatment modality~* At least 50 Gray of radiation treatment to areas of the oral cavity/oropharynx mucosa that can be visualized~* Concurrent chemotherapy regimen of Cisplatin 100mg/m\^2 on days 1, 22, and 43~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal to 2~* Adequate hematologic, renal and hepatic function~* Negative pregnancy test by serum or urine~* Signed informed consent~Key Exclusion Criteria:~- Presence or history of any other primary malignancy (other than curatively treated in situ cervical cancer, or basal cell carcinoma of the skin without evidence of disease for greater than 3 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palifermin (Type: EXPERIMENTAL): Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.

Based on this trial design, predict the completion outcome and termination type (if applicable).